ponatinib versus ascimininib in the third-line treatment of cml
Published 1 year ago • 446 plays • Length 1:17Download video MP4
Download video MP3
Similar videos
-
2:27
ascembl: asciminib versus bosutinib in third-line treatment of cp-cml
-
2:49
outcomes of patients with cml-cp treated with ponatinib vs 2g-tkis in the third-line setting
-
2:51
the use of asciminib versus ponatinib for multiresistant cml
-
1:46
asciminib versus other tkis in the frontline treatment of cml: the asc4first study
-
1:08
managing drug resistance in cp-cml with ponatinib and asciminib
-
1:49
mitosis: how spindle assembly checkpoint ensures correct chromosome segregation during cell division
-
1:46
ruxolitinib in 2024 and beyond: the good, the suboptimal, and the failure
-
6:31
an overview of trials investigating asciminib in the treatment of ph cml
-
1:10
tolerability of bosutinib vs asciminib in heavily pre-treated patients with cml
-
1:16
ponatinib for cml and ph all: five-year results from the pace trial
-
1:35
safety of ponatinib in chronic-phase chronic myeloid leukemia (cml) patients
-
4:19
optic: ponatinib in resistant chronic-phase cml
-
1:37
optic: ponatinib in chronic-phase cml
-
2:12
5-year update of bfore: bosutinib vs imatinib in cml
-
1:17
decitabine, venetoclax and ponatinib in patients with advanced cml and ph aml
-
1:03
phase i study of asciminib in patients with cp-cml carrying the t315i mutation
-
0:55
phallcon: phase iii study of ponatinib vs imatinib in newly diagnosed ph all
-
1:35
long-term follow-up from the oiti trial: ponatinib in patients with cml in italy
-
1:10
final results of the bfore trial: bosutinib vs imatinib in cp-cml
-
1:40
using ponatinib to treat highly resistant chronic myeloid leukemia, results from a phase i trial
-
1:32
novel btki strategies in indolent b-cell malignancies: pirtobrutinib for fl and mzl
-
5:41
update on phase ii study of hyper-cvad with ponatinib in patients with ph all